STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Z
Active, not recruiting
- Abiraterone Acetate
- +4 more
- Abiraterone acetate tablets
- Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
2021-12-30
Dec 30, 2021A
Completed
- Prostate Cancer
- Abiraterone acetate standard dose
- Abiraterone acetate escalated dose
- Paris, FranceDepartment of Medical Oncology, Cochin Hospital
2022-01-21
Jan 21, 2022A
Active, not recruiting
- Prostate Cancer
- ARN-509
- +2 more
- Boston, Massachusetts(unnamed)
2022-03-24
Mar 24, 2022A
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
- Los Angeles, California
- +6 more
2022-03-24
Mar 24, 2022J
Completed
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Abiraterone Acetate Tablets (I)
- ZYTIGA®
- Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
2022-02-16
Feb 16, 2022U
Suspended
- Castration-Resistant Prostate Carcinoma
- +6 more
- Abiraterone Acetate
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-02-09
Feb 9, 2022W
Not yet recruiting
- Prostatic Neoplasms, Castration-Resistant
- Drug Therapy, Combination
- TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
- Chengdu, Sichuan, ChinaWest China Hospital
2021-12-12
Dec 12, 2021T
Completed
- Healthy Volunteers
- Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)
- Qingdao, Shangdong, ChinaPhase I Clinical Research Center
2021-04-26
Apr 26, 2021F
Completed
- Prostate Cancer
- AA Reduced dose-normal diet (A)
- +2 more
- Seville, SpainHospital Universitario Virgen del Rocío
2021-01-08
Jan 8, 2021M
Active, not recruiting
- Prostate Cancer
- Boston, MassachusettsMassachusetts General Hospital
2021-02-08
Feb 8, 2021F
Completed
- Salivary Glands Tumors
- Abiraterone acetate
- Milan, Lombardy, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
2021-03-01
Mar 1, 2021D
Active, not recruiting
- Prostate Cancer
- Apalutamide
- +3 more
- La Jolla, California
- +3 more
2021-09-01
Sep 1, 2021M
Active, not recruiting
- Prostate Cancer
- Abiraterone acetate 1000 mg po daily
- +2 more
- New York, New York
- +3 more
2021-09-01
Sep 1, 2021C
Completed
- Pharmacogenetic Study
- Abiraterone Acetate
- Nice, FranceCentre Antoine Lacassagne
2020-12-03
Dec 3, 2020U
Completed
- Hormone-Resistant Prostate Cancer
- +3 more
- Abiraterone Acetate
- +3 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2021-04-22
Apr 22, 2021M
Active, not recruiting
- Prostate Cancer
- Evanston, Illinois
- +2 more
2021-09-09
Sep 9, 2021M
Completed
- Prostate Cancer
- Abiraterone acetate
- +2 more
- Chicago, Illinois
- +15 more
2021-10-25
Oct 25, 2021J
Completed
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Abiraterone acetate
- Prednisone
- Aurora, Colorado
- +21 more
2021-07-22
Jul 22, 2021D
Completed
- Prostate Cancer
- Enzalutamide
- +2 more
- Durham, North CarolinaDuke University Medical Center
2020-12-22
Dec 22, 2020J
Recruiting
- Prostate Cancer
- Abiraterone Acetate
- Bangalore, India
- +6 more
2022-03-24
Mar 24, 2022D
M
Active, not recruiting
- Prostatic Neoplasms
- Abiraterone Acetate
- Prednisone
- Bronx, New YorkMontefiore Medical Center
2021-12-02
Dec 2, 2021W
Not yet recruiting
- Prostate Cancer
- Abiraterone acetate
- +2 more
- Chengdu, Sichuan, ChinaWest China Hospital
2021-02-03
Feb 3, 2021H
Active, not recruiting
- Prostate Cancer
- Abiraterone Acetate
- Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
2022-01-28
Jan 28, 2022M
Active, not recruiting
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
- Abiraterone Acetate
- +7 more
- Houston, TexasM D Anderson Cancer Center
2021-11-17
Nov 17, 2021